Raising Healthcare Standards

Contact Us | Glossary | Site Map | Links | Help | Accessibility | Low Graphics |  Text Size: A |  A+ |  A++

Advanced Search

The use of B-type natriuretic peptide (BNP) in the investigation of patients with suspected heart failure

This project is now complete.

Click here to access the final report.
 
The information below is for reference purposes.

Project Introduction

Heart failure is a complex syndrome in which the ability of the heart to function as a pump is impaired. It is one of the main reasons for hospitalisation in Scotland and is associated with high mortality.

There is evidence that a blood test which measures B-type natriuretic peptide (BNP) or N-terminal pro BNP (NT-Pro-BNP), peptide hormones produced in the heart, aids the diagnosis of heart failure because plasma BNP or NT-Pro-BNP concentrations are raised in patients with heart failure. This Short Health Technology Asessment (Short HTA) will test whether or not a negative BNP or NT-Pro-BNP result can reliably rule out heart failure and whether or not a positive result can increase the accuracy of diagnosis.

The aim of this Short HTA is to establish the place of BNP or NT-Pro-BNP in the diagnosis of heart failure in Scotland and determine the associated costs and benefits of the strategy which will be recommended as a result of the assessment.

Expected Date of Publication:

February 2005

Additional Information:

The following links will provide additional information on this project: